Group 1: Annual Reports and Dividends - Gujinggong Liquor (000596) reported 2024 revenue of 23.578 billion yuan, up 16.41%, and net profit of 5.517 billion yuan, up 20.22%. The company plans to distribute a cash dividend of 50 yuan per 10 shares, totaling 2.643 billion yuan [2] - Luzhou Laojiao (000568) reported 2024 revenue of 31.196 billion yuan, up 3.19%, and net profit of 13.473 billion yuan, up 1.71%. The company plans to distribute a cash dividend of 45.92 yuan per 10 shares, totaling 6.759 billion yuan [2] - Gree Electric (000651) reported 2024 revenue of 189.164 billion yuan, down 7.26%, and net profit of 32.185 billion yuan, up 10.91%. The company plans to distribute a cash dividend of 20 yuan per 10 shares, totaling 11.17 billion yuan [3] Group 2: Q1 2025 Performance - Gujinggong Liquor reported Q1 2025 revenue of 9.146 billion yuan, up 10.38%, and net profit of 2.330 billion yuan, up 12.78% [2] - Gree Electric reported Q1 2025 revenue of 41.507 billion yuan, up 14.14%, and net profit of 5.904 billion yuan, up 26.29% [3] - National City Mining (000688) reported Q1 2025 revenue of 0.053 billion yuan, up 77.25%, and net profit of 0.0612 billion yuan, up 18279.65% [4] - Taiyuan Iron & Steel (000825) reported Q1 2025 revenue of 23.31 billion yuan, down 4.71%, and net profit of 0.0188 billion yuan, up 5506.92% [4] - Shenfang A (000029) reported Q1 2025 revenue of 0.033 billion yuan, up 457.38%, and net profit of 0.0724 billion yuan, up 3718.51% [4] - Qingda Environmental Protection (688501) reported Q1 2025 revenue of 0.0619 billion yuan, up 317.43%, and net profit of 0.0687 billion yuan, up 990.26% [4] - Tianbao Infrastructure (000965) reported Q1 2025 revenue of 0.0169 billion yuan, down 34.62%, and net profit of 0.01 billion yuan, up 737.29% [4] - Taihe Intelligent (603656) reported Q1 2025 revenue of 0.0105 billion yuan, up 10.19%, and net profit of 0.0002097 billion yuan, up 716.41% [5] - Meg Intelligent (002881) reported Q1 2025 revenue of 0.0997 billion yuan, up 73.57%, and net profit of 0.0463 billion yuan, up 616.02% [5] - Shengda Biological (603079) reported Q1 2025 revenue of 0.0203 billion yuan, up 9.95%, and net profit of 0.0217 billion yuan, up 469.35% [5] - Jincai Interconnection (002530) reported Q1 2025 revenue of 0.0206 billion yuan, down 33%, and net profit of 0.001364 billion yuan, up 466.95% [5] - XinSai Co. (600540) reported Q1 2025 revenue of 1.215 billion yuan, up 312.03%, and net profit of 0.01819 billion yuan, up 315.74% [6]

Core Viewpoint - The company has announced the use of idle raised funds for cash management, specifically investing in structured deposits with a total amount of 80 million RMB, aiming to enhance the efficiency of fund utilization and increase returns for the company and its shareholders [1][2][8]. Summary by Relevant Sections Investment Overview - The purpose of the investment is to improve the efficiency of raised funds and ensure that the investment does not affect the construction and use of the raised funds, while also increasing returns for the company and shareholders [2][9]. - The total amount for cash management is set at 80 million RMB, with a maximum limit of 230 million RMB for temporary idle funds [1][2]. - The funds are sourced from a specific stock issuance approved by the China Securities Regulatory Commission, raising a total of 267.61 million RMB, with a net amount of 261.42 million RMB after deducting issuance costs [2][3]. Investment Details - The investment will be made in structured deposits from China Construction Bank, with a principal amount of 40 million RMB and a term of 32 days, expected to yield a floating return [5][8]. - The expected annualized return ranges from 0.65% to 2.4%, depending on market conditions [5][7]. Approval and Compliance - The investment plan was approved during the 18th meeting of the fourth board of directors and the 16th meeting of the supervisory board on July 7, 2025, and does not require further shareholder approval [1][8][10]. - The company will manage the cash management products in compliance with relevant regulations and ensure that the funds are returned to the special account for raised funds upon maturity [8][10]. Impact on Operations - The use of idle funds for cash management is not expected to affect the company's daily operations or the normal progress of investment projects, and it aims to enhance the returns on cash assets [9][10]. - The company will adhere to the "New Financial Instruments Standards" in handling the cash management products, which may impact various financial statement items [9][10]. Monitoring and Risk Management - The company will maintain close contact with financial institutions to monitor the operation of cash management funds and strengthen risk control [10]. - The supervisory board and the sponsor institution have confirmed that the decision-making and approval processes are legal and compliant, ensuring no harm to the interests of the company and its shareholders [10][11].

证券代码：603079 证券简称：圣达生物 公告编号：2025-037 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：中国建设银行浙江分行单位人民币定制型结构性存款 投资额度：8,000.00万元 已履行的审议程序：浙江圣达生物药业股份有限公司（以下简称"公 司"）于2025年7月7日召开第四届董事会第十八次会议和第四届监事会第十六次 会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司及 子公司使用额度不超过人民币23,000.00万元的暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、产品期限不超过12个月的银行等金 融机构现金管理产品（包括但不限于结构性存款、大额存单等）。在上述期限及 额度内，资金可滚动使用，并授权公司董事长最终审定并签署相关实施协议或者 合同等文件。保荐机构对此出具了明确的核查意见。 特别风险提示：尽管公司使用闲置募集资金进行现金管理购买的产品属于 低风险投资品种 ...

Core Points - Zhejiang Shengda Bio-Pharm Co., Ltd. is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][4] - The company was approved by the China Securities Regulatory Commission to issue 20 million shares of common stock to the public and was listed on the Shanghai Stock Exchange on August 23, 2017 [2][4] - The registered capital of the company is RMB 189,029,624 [3][4] - The company's business scope includes drug production, feed additives production, food additives production, and hazardous chemicals production, among others [4][5] Company Structure - The company is structured as a permanent joint-stock company with all assets divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [3][4] - The company has established a party organization in accordance with the regulations of the Communist Party of China, which plays a political core role within the company [2][3] Share Issuance and Management - The shares of the company are issued in the form of stocks, with each share having a par value of RMB 1 [5][6] - The total number of shares issued by the company is 189,029,624, all of which are common shares [6][7] - The company cannot provide any financial assistance to individuals or entities purchasing its shares [6][7] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in shareholder meetings, as well as the obligation to comply with laws and regulations [12][13] - The company must maintain a shareholder register based on the records provided by the securities registration agency [12][13] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [43][44] - Shareholder meetings must be conducted in accordance with legal and regulatory requirements, and the company must provide legal opinions on the meeting's compliance [46][47] Voting and Resolutions - Resolutions at shareholder meetings can be classified as ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [76][77] - The company must ensure that voting rights are exercised fairly, and any related party transactions must be disclosed and voted on without the participation of related shareholders [80][81]

Meeting Overview - The fourth supervisory board meeting of Zhejiang Sandar Biopharmaceutical Co., Ltd. was held on July 7, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1][2]. Resolutions Passed - The supervisory board approved the proposal to use raised funds to replace pre-invested project funds and paid issuance expenses, with a unanimous vote of 3 in favor [1][2]. - The board also approved the proposal to provide loans from raised funds to the controlling subsidiary for project implementation, again with a unanimous vote of 3 in favor [2]. - A resolution was passed to manage idle raised funds for cash management purposes, receiving unanimous approval [2]. - The board approved the use of idle self-owned funds for cash management, also with unanimous support [2][3].

重要内容提示： 召开的日期时间：2025 年 7 月 23 日 13 点 30 分 召开地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 证券代码：603079 证券简称：圣达生物 公告编号：2025-036 浙江圣达生物药业股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 23 日 至2025 年 7 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-035 关于修改《公司章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江圣达生物药业股份有限公司（以下简称"公司"）于2025年7月7日召 开第四届董事会第十八次会议，会议审议通过《关于修改 <公司章程> 并办理工 商变更登记的议案》。本议案尚需提交公司2025年第二次临时股东大会审议。 修订的原因及具体条款如下： 一、变更的原因 （一）向特定对象发行股票 经中国证券监督管理委员会《关于同意浙江圣达生物药业股份有限公司向 特定对象发行股票注册的批复》（证监许可2025165号）文件核准，公司向特 定对象发行人民币普通股（A股）股票（以下简称"本次发行"）17,840,666股， 每股发行价格为人民币15.00元，募集资金总额为人民币267,609,990.00元，扣 除 发 行 费用（ 不 含税） 人民 币 6,186,644.91 元后， 募集资 金净额为人 民币 行的股票自本次发行结束之日起6个月内不得转让。 公司本次发 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-031 浙江圣达生物药业股份有限公司 关于使用募集资金置换预先投入募投项目 及已支付发行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 浙江圣达生物药业股份有限公司（以下简称"公司"、"圣达生物"） 拟使用募集资金置换预先已投入募集资金投资项目的自筹资金的金额为人民币 间距离募集资金到账时间不超过6个月，符合相关法规的要求。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江圣达生物药业股份有限公司向 特定对象发行股票注册的批复》（证监许可2025165号）文件核准，浙江圣达 生物药业股份有限公司向特定对象发行人民币普通股（A股）股票17,840,666 股，每股发行价格为人民币15.00元，募集资金总额为人民币267,609,990.00 元，扣除发行费用（不含税）人民币6,186,644.91元后，募集资金净额为人民 币261,423,345.09元。 上述募集资金到位情况业经天健会计师事务所（特殊普通合伙） ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-034 浙江圣达生物药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 投资种类：安全性高、流动性好的低风险现金管理产品，包括但不限于 存款类产品、收益凭证、货币及债券类现金管理产品等，但不包括股票投资、 外汇投资、期货投资及房地产投资。 ? 投资金额：不超过人民币2.00亿元。在上述额度范围内，资金可滚动使 用。 ? 已履行的审议程序：浙江圣达生物药业股份有限公司（以下简称"公 司"）于2025年7月7日召开第四届董事会第十八次会议和第四届监事会第十六 次会议，审议通过了《关于使用闲置自有资金进行现金管理的议案》。本事项 无需提交公司股东大会审议。 ? 特别风险提示：尽管公司使用闲置自有资金进行现金管理购买的产品属 于低风险投资品种，总体风险可控，但金融市场受宏观经济的影响较大，不排 除该项投资受到市场波动的影响，存在一定的系统性风险。公司将积极采取相 关措施防范和控制投资风险，敬请广 ...

中信建投证券股份有限公司 关于浙江圣达生物药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 中信建投证券股份有限公司（以下简称"保荐机构"）作为浙江圣达生物药 业股份有限公司（以下简称"圣达生物"或"公司"）向特定对象发行股票的保 荐机构，根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引第 11 号 ——持续督导》等有关规定，对圣达生物使用闲置募集资金进行现金管理的事项 进行了审慎核查，具体情况如下： 一、本次使用闲置募集资金进行现金管理情况概述 （一）投资目的 为提高募集资金使用效率，合理利用暂时闲置募集资金，在确保不影响募集 资金投资项目建设和使用、募集资金安全的情况下，增加公司的收益，为公司及 股东获取更多回报。 公司及子公司拟使用额度不超过人民币 23,000.00 万元的暂时闲置募集资金 进行现金管理，适时用于购买安全性高、流动性好、有保本约定、产品期限不超 过 12 个月的银行等金融机构现金管理产品（包括但不限于结构性存款、大额存 单等）。在确保不影响募集资金投资项目建设和募集资金使用的情况下，资金可 在有 ...